{"id":"ask120067","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without publicly available clinical trial data or mechanism disclosures, the precise molecular target and pharmacological action of ASK120067 remain unknown. The drug is currently in phase 3 clinical development, indicating it has progressed beyond early-stage testing but full mechanistic details are typically proprietary until regulatory submission or publication.","oneSentence":"ASK120067 is an investigational therapeutic agent in phase 3 development by Jiangsu Aosaikang Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:41.189Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07413952","phase":"PHASE2","title":"Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2026-04-01","conditions":"NSCLC","enrollment":45},{"nctId":"NCT05306132","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067","status":"RECRUITING","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","startDate":"2022-08-08","conditions":"Advanced Solid Tumor","enrollment":150},{"nctId":"NCT06982924","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-06-30","conditions":"EGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive","enrollment":136},{"nctId":"NCT04143607","phase":"PHASE3","title":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","startDate":"2019-07-23","conditions":"Locally Advanced or Metastatic NSCLC","enrollment":337},{"nctId":"NCT05631678","phase":"PHASE1","title":"Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole","status":"COMPLETED","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","startDate":"2022-06-06","conditions":"Locally Advanced or Metastatic NSCLC","enrollment":48},{"nctId":"NCT03502850","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","startDate":"2017-11-30","conditions":"Locally Advanced or Metastatic NSCLC","enrollment":507},{"nctId":"NCT04360915","phase":"PHASE1","title":"Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","startDate":"2019-12-09","conditions":"Locally Advanced or Metastatic NSCLC","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Limertinib"],"phase":"phase_3","status":"active","brandName":"ASK120067","genericName":"ASK120067","companyName":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","companyId":"jiangsu-aosaikang-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}